Skip to content

High intensity exercise for non-alcoholic steatohepatitis- is it safe, effective, and feasible in practice?

In patients with non-alcoholic steatohepatitis, is high intensity interval training safe, feasible and effective for improving fitness and insulin sensitivity.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000305426
Enrollment
14
Registered
2016-03-09
Start date
2016-06-03
Completion date
2020-02-26
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Regular aerobic exercise has now been established as an effective therapy for reducing liver fat in patients with non-alcoholic fatty liver disease (NAFLD), even in the absence of weight loss. However the efficacy of regular exercise in progressive liver disease such as non-alcoholic steatohepatitis (NASH) is yet to be established. Recent evidence has suggested that high intensity exercise may be required for benefit and, as such, high intensity interval training (HIIT) may be an effective modality for improving cardiovascular, metabolic and liver health in patients with NASH. A key feature to the success of any exercise intervention is the ability to adhere to the intervention in the long-term. The ability to perform HIIT on a regular basis, in an unsupervised environment has yet to be determined. The aims are to i) examine the efficacy of a 12 week supervised exercise intervention involving high-intensity interval training (HIIT) in patients with biopsy-proven non-alcoholic steatohepatitis (NASH) for improving cardiorespiratory fitness (CRF), and ii) examine the safety and feasibility of regular HIIT in patients with NASH both when performed under supervision and when performed unsupervised (home-based, for 12 weeks). We hypothesise that, compared with control: i) the HIIT intervention will significantly improve CRF, and ii) the HIIT intervention will be safe and feasible for sustaining both supervised and unsupervised exercise adherence in people with NASH. Eligible participants (n=22) will be randomised into 12 weeks of HIIT (n=11) or a control (n=11). The primary analysis will examine the efficacy of 12 weeks of HIIT on changes in cardiorespiratory fitness, body composition, liver fat, liver stiffness, abdominal visceral fat, vascular function, and other cardio-metabolic risk factors, compared with control. The supervised HIIT training will begin with a warm-up for 5 min and at 60% of maximal heart rate (HRmax) followed by 4 x 4 min intervals at 85-95% HRmax interspersed with 3 min ‘recovery’ periods at 60% HRmax, then a 5 min cool down. Participants randomised to the control group will perform 12 weeks of stretching and then be invited to complete the HIIT protocol. On completion of the HIIT intervention, all participants (n=22) will be prescribed an on-going exercise program based on an equivalent type and intensity of exercise, modified for an unsupervised home/gym environment. Feasibility and adherence will be assessed via self-administered questionnaires and focus group after 12 weeks of home based exercise.

Interventions

Participants will receive 12 weeks of supervised High Intensity Interval Training (HIIT), followed by 12 weeks of home-based HIIT (in an unsupervised environment). The HIIT protocol will consist of: warm-up for 5 min and at 60% of maximal heart rate (HRmax) followed by 4 x 4 min intervals at 85-95% HRmax interspersed with 3 min ‘recovery’ periods at 60% HRmax, then a 5 min cool down. All training will be conducted on three days per week. Weeks 1-12 will be supervised by an Accredited Exercise Ph

Participants will receive 12 weeks of supervised High Intensity Interval Training (HIIT), followed by 12 weeks of home-based HIIT (in an unsupervised environment). The HIIT protocol will consist of: warm-up for 5 min and at 60% of maximal heart rate (HRmax) followed by 4 x 4 min intervals at 85-95% HRmax interspersed with 3 min ‘recovery’ periods at 60% HRmax, then a 5 min cool down. All training will be conducted on three days per week. Weeks 1-12 will be supervised by an Accredited Exercise Physiologist and weeks 13-24 will be home-based (unsupervised).. Sessions will be generally conducted one-on-one with a maximum of 3 participants training at one time. All supervised sessions will be recorded on a clinical resource form and all home-based sessions will be recorded in an exercise log. Participants will be given a Polar heart rate monitor and taught how to monitor the intensity of their exercise sessions using heart rates and ratings of perceived exertion (RPE). All supervised exercise will be conducted on a treadmill, unless orthopaedic limitation exists in which a cycle ergometer will be used. Home-based exercise will involve walking/jogging or cycling depending on the access to exercise equipment and preferences of the individual participant.

Sponsors

The University of Queensland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Men and women who are not currently meeting physical activity guidelines (<150 minutes of moderate or <75 min of vigorous exercise per week), aged 18-70 years, with biopsy-proven NASH.

Exclusion criteria

Unstable angina; Recent (4 weeks) myocardial infarction; Coronary Artery Disease; Uncompensated heart failure; New York Heart Association (NYHA) Functional Classification II-IV; Severe valvular illness; Pulmonary disease; Uncontrolled hypertension (systolic blood pressure > 200 mmHg and/or diastolic blood pressure >110 mmHg); Renal failure (Chronic Kidney Disease stages III-V); Orthopedic/neurological limitations; Cardiomyopathy; Planned operations during the research period; Physical impairment limiting the ability to exercise; Drug or alcohol abuse; Planning to or participation in another study; Not willing to sign the consent from; Females pregnant or expecting to be pregnant during the study period; Lactating females; Contraindication to exercise testing/training; Medication affecting insulin sensitivity and/or evidence of cirrhosis; Any other reason which would limit their ability to participate in this study.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 10, 2026